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Random Forest screening of the phytochemical constituents of 240 herbs used in traditional 
Chinese medicine identified a number of compounds as potential inhibitors of the human 
aromatase enzyme (CYP19). Molecular modelling/docking studies indicated that three of 
these compounds (myricetin, liquiritigenin and gossypetin) would be likely to form stable 
complexes with the enzyme. The results of the virtual screening studies were subsequently 
confirmed experimentally, by in-vitro (fluorimetric) assay of the compounds’ inhibitory 
activity. The IC-50s for the flavones, myricetin and gossypetin were determined as 10 µM and 
11 µM, respectively, whilst the flavanone, liquiritigenin, gave an IC-50 of 0.34 µM – showing 
about a 10 fold increase in potency, therefore, over the first generation aromatase inhibitor, 
aminoglutethimide. 
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Introduction 
 
Around one-in-nine women in the UK are diagnosed with breast cancer at some point in their 
life [1], and 50-80% of these suffer tumours that are oestrogen-dependent [2] – with the 
tumour cells expressing oestrogen receptors, and the growth of the tumours being stimulated 
by circulating oestrogen. These oestrogen-dependent mammary carcinomas can be combated 
through the use of anti-oestrogens (like tamoxifen), that interfere with the binding of 
oestrogen to its receptor, or else through the use of aromatase inhibitors, that act to decrease 
the circulating levels of oestrogen by blocking the biosynthesis of the compound from 
androgens [3]. 
 
Aromatase, also known as CYP19, is produced to high levels in breast tissue, and particularly 
in those areas in and around tumour sites [3]. The enzyme is competitively inhibited by 
steroidal compounds like exemastane, but also by various non-steroidal compounds, such as 
aminoglutethimide (Figure 1). The orally-active, potent, and highly selective (third 
generation) aromatase inhibitors that are licensed for clinical use (in the treatment of 
metastatic oestrogen-dependent breast cancer in postmenopausal women) include anastrozole, 
letrosole and exemastane (Figure 1). 
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Other known inhibitors of the enzyme include various flavonoid compounds, in particular 
those based on the flavone and flavanone skeletons [3]. These compounds have attracted 
considerable interest in regard to aromatase inhibition, in part because of the hypothesis put 
forward that these natural products may represent dietary factors that account for the 
significantly lower incidence of breast cancer among women of Asian and Oriental origin [4], 
and also because of the reported general inverse association between the incidence of breast 
cancer and consumption of flavonoid-rich vegetables [5-6]. 
 
In the work reported here, the aim was to use the structural data on the phytochemical 
constituents from herbs commonly used in traditional Chinese medicines, to prospect for 
novel aromatase inhibitors, using a combination of multiple decision tree (Random Forest) 
modelling and molecular docking studies, with the hits identified through these in-silico 
predictions then confirmed through laboratory-based experiments. 
 
 
Methods 
 
Random Forest Modelling Structural data on the known phytochemical constituents of 240 
herbs widely used in traditional Chinese medicine were taken from the Chinese Herbal 
Constituents Database (CHCD) [7]. A total of 238 different structural descriptors for these 
compounds were then computed; specifically, the full set of 150 2D MOE descriptors 
(Chemical Computing Group, Montreal, Quebec), 56 Kier-Hall descriptors [8-9], and 32 
Labute VSA descriptors [10]. Random Forest (RF) models for prediction of aromatase 
inhibitory activity were derived using activity data taken from the Bio-active Plant 
Compounds Database (BPCD) [7]. The RF modelling, performed using Random Forests, 
version 1 (Salford Systems, San Diego, California) was carried out as described by Ehrman et 
al [11-12]. The MOE, Kier-Hall and Labute descriptor sets were used in generating three 
separate RF models, each comprising an ensemble of 500 decision trees. For each tree in the 
ensemble, a bootstrap sample was randomly chosen from the minority class of 44 BPCD 
compounds with known anti-aromatase activity, and the same number of cases then randomly 
selected to add to this group from the majority class of 8,264 CHCD compounds. Decision 
trees were then constructed, following the CART algorithm, and employing the Gini splitting 
criterion (see [11-12]). The error rates associated with the resulting RF predictions were 
quantified using the technique of “out-of-bag” (OOB) cross-validation, with ~33% of the 
bootstrap compounds withheld for each tree trained in order to provide an independent test 
sample. By such means the prediction performance of the RF is measured by taking the OOB 
sample for each tree, running it through that tree, computing the associated error rate, and 
then averaging the error rates over all 500 trees to obtain the mean misclassification rate for 
the entire forest. The mean misclassification rates thus obtained (calculated with an RF cut-off 
value of 0.5) were 30%, 21%, and 32%, for the RF models generated using the MOE, Kier-
Hall and Labute descriptor sets, respectively. In the present work, however, much more 
stringent criteria were employed to identify potential aromatase inhibitors: the CHCD 
compounds taken as hits being those that achieved aromatase activity RF scores of ≥ 0.8 in at 
least two of the three RF models (a score of 0.8 here meaning that 80% of the decision trees 
within a given RF model voted for a compound to exhibit aromatase activity). By such means 
the resulting predictions were made more dependable, but with the attendant limitation that 
the CHCD hits would then be (structurally) very similar to the bioactive compounds most 
numerous in the RF training set, viz., the flavonoids. 
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Molecular Modelling  The construction of molecular models of potential aromatase 
inhibitors, and the docking of these ligands into the enzyme active site, were first performed 
using Hyperchem™ version 7 (Hypercube Inc., Gainesville, Florida). The atomic co-ordinates 
for the homology modelled structure of human aromatase were downloaded from the Protein 
Data Bank [13] (accession code, 1TQA, [14] ). Ligands were initially docked manually, and 
the resulting complexes then optimised using the AMBER force field [15], with Polak-Ribière 
conjugate gradient minimisation to a final potential energy gradient of 0.001 kcal.mole-1.Å-1. 
For each of the three ligands, a total of five initial poses were considered (with superposed 
centroids but varying orientations), and the optimisation of these complexes performed with 
movement allowed only to the ligand atoms (all protein atoms being treated as fixed). Further 
docking studies were subsequently performed using the FlexX program [16] (BioSolveIT 
GmbH, Sankt Augustin, Germany). In this case, the protein residues involved in the binding 
site for each ligand were defined with reference to the ligand pose in the most stable of the 
Hyperchem™-modelled complexes. The FlexX docking was in all cases performed without 
constraints, and using the default values for all adjustable control parameters. 
 
In-vitro assay of aromatase inhibitory activity Liquiritigenin (7-hydroxy-2-(4-
hydroxyphenyl)chroman-4-one), gossypetin (2-(3,4-dihydroxyphenyl)-3,5,7,8-
tetrahydroxychromen-4-one) and myricetin (3,5,7-trihydroxy-2-(3,4,5-
trihydroxyphenyl)chromen-4-one) were purchased from LGC Standards Ltd (Teddington, 
UK) and were used as received. Aromatase inhibition assays were performed using the 
CYP19/MFC high-throughput screening kit (BD Biosciences, Oxford, UK). Substrate for the 
reaction was 7-methoxy-4-trifluoromethyl coumarin (MFC). Enzyme reactions were 
performed, according to the manufacturer’s protocol, using ethanol solutions of the potential 
inhibitors, in Greiner (flat bottom, black) 96-well plates (Sigma, Dorset, UK), with 
fluorescence measurements recorded using a FLUOstar Optima (BMG Labtech Ltd, 
Aylesbury, UK), and employing an excitation wavelength of 405 nm and emission 
wavelength of 520 nm. All assays were performed at ambient, and fluorescence 
measurements recorded at five-minute intervals over a period of 1 hr. A CYP19 concentration 
of 7.5 nM was employed, with a fixed substrate concentration of 25 µM. Fluorescence-time 
profiles for each reaction were corrected for background fluorescence, and the initial catalytic 
rates in the presence of inhibitor expressed as a fraction of the rate for the uninhibited 
enzyme. The assays for the TCM constituents were carried out in duplicate on two separate 
occasions, but the assay for ketoconazole was carried out only in triplicate (on a single 
occasion). 
 
 
Results & Discussion 
 
The structural features of 44 phytochemicals with known aromatase activity were used in 
training Random Forest (RF) models to distinguish likely aromatase inhibitors in 8,264 
constituents of 240 different herbs used in traditional Chinese medicine (TCM). The 
compounds with known aromatase activity comprised eighteen assorted flavonoids (55% of 
the total), nine sesquiterpenes (27% of the total), with the remainder including alkaloids, 
tannins, lignans, di- and tri-terpenes, aliphatics and sterols. The trivial names for the 30 TCM 
compounds achieving the highest RF scores in this screening are listed in Table 1, along with 
their systematic names, botanical source(s) and anti-aromatase RF scores. Several of the hits 
identified are for compounds already known to inhibit the aromatase enzyme, including 
apigenin (with an IC-50 of ~1 µM) [17], and diadzein, genistein, and galangin (with Ki values 
of the order of 100 µM) [18]. Of the 22 compounds in this short list that do not appear yet to 
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have been tested for anti-aromatase activity, three compounds, namely, liquiritigenin, 
gossypetin, and myricetin could be obtained commercially. These compounds (the chemical 
structures for which are shown in Figure 2) were selected for further study. Myricetin has 
long been recognised as an anti-oxidant [19] and is also shown to inhibit mitogen-activated 
protein kinase kinase [20]. Liquiritigenin has been shown to have apoptotic [21] and cytotoxic 
[22] effects, and also to inhibit tyrosinase [23] and monoamine oxidase [24]. Gossypetin has 
previously been shown to have anti-inflammatory [25] and anti-allergic [26] activity. 
 
In order to provide a further test of the likely inhibitory activity of the three chosen herbal 
constituents against human aromatase, in-silico experiments were conducted to dock the 
ligands into the enzyme binding site, both manually and using the FlexX [16] software. For 
each ligand, various initial poses were considered, but all in the vicinity of residues previously 
identified (on the basis of the model building studies) as lining the enzyme active site pocket 
[14]. These residues - many of which have also been demonstrated to be key determinants in 
ligand binding through site-directed mutagenesis experiments [18, 27-30] – include Glu 302, 
Thr 310, Ser 478 and His 480. 
 
On the basis of the manual docking, it was shown that the two flavones, gossypetin and 
myricetin did not give as good a fit to the enzyme binding site as the flavanone, liquiritigenin. 
For the flavones, the potential energies of the complexes were in the range -88 - -67 kJ.mole-1 
and -67 - -38 kJ.mole-1 (for myricetin and gossypetin, respectively), whereas the energies for 
the liquiritigenin complexes lay in the range -105 - -84 kJ.mole-1. On the basis of the manual 
docking, therefore, liquiritigenin was predicted to show a greater inhibitory activity against 
aromatase than either of the two flavones. Liquiritigenin, with its L-shaped form, dictated by 
the conformational flexibility of the heterocyclic ring and the α-substituent at C-2, appears 
better suited to the shape of the enzyme binding site than the more planar flavones (see Figure 
3). Although the most stable of the manually docked liquiritigenin complexes showed no 
protein-ligand hydrogen bonds, such interactions were seen in some of the lower ranked 
structures, typically between the ring hydroxyls and various sites on the protein main chain.  
 
In the FlexX docking studies, the highest scoring (most stable) complexes were found to be 
those involving myricetin and gossypetin. The energies for the top 20 poses ranged from -23 
to -13 kJ.mole-1 for myricetin, and from -20 to -12 kJ.mole-1for gossypetin. In contrast, the top 
20 poses for liquiritigenin complexes gave energies in the range -18 to -9 kJ.mole-1. 
Inspection of the FlexX modelled complexes for the two flavone ligands revealed that the 
improved binding was often associated with a twisting of the chromene and phenyl rings – 
with the C2-C1’ dihedral angle generally increased from ~0o to ~60o (see Figure 4). Such 
twisting (which was not seen in any of the Hyperchem™ optimised models) seemed to allow 
for greater protein-ligand hydrogen bonding. 
 
It was found, therefore, that the FlexX and manual docking studies were not consistent: the 
latter suggested that the order of anti-aromatase activities would be myricetin > gossypetin > 
liquiritigenin, whereas the former suggested that the order would be liquiritigenin > myricetin 
> gossypetin. Laboratory-based assays were thus conducted for all of the compounds. 
 
In-vitro testing of the activities of the putative aromatase inhibitors was carried out by means 
of a coupled fluorometric assay, monitoring the reduction in fluorescence associated with 
formation of the CYP19 product (7-hydroxy-4-trifluoromethyl coumarin). IC-50s for each 
inhibitor, including that for the positive control, ketoconazole, were determined from the 
percentage inhibition-concentration plots (Figure 5). For the flavones, myricetin and 
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gossypetin, (Figure 5B,C) the IC-50s were found to be 10 µM and 11 µM, respectively, 
whereas that for the flavanone, liquiritigenin (Figure 5A) was found to be 0.34 µM. The IC-50 
for ketoconazole (Figure 5D) was recorded as 3 µM – consistent with the value of 3.8 µM 
quoted by the suppliers. 
 
It is seen, therefore, that the rank ordering of the activities for the three TCM compounds 
agrees with the ordering predicted on the basis of the manual docking studies, but not that 
predicted on the basis of the FlexX docking studies. In part this might be attributed to the 
emphasis given by FlexX to establishing hydrogen bonding between the ligands and protein – 
such that the polyhydroxylated flavones erroneously appear capable of forming more 
extensive interactions with the aromatase enzyme than the (dihydroxy) flavanone, 
liquiritigenin. It must also be borne in mind, however, that the agreement between the manual 
docking and in-vitro test results may be entirely fortuitous, since neither the manual docking 
nor the FlexX docking studies allowed for any conformational changes in the protein, nor did 
they take into account the associated entropic changes (with the stability of the complexes 
judged purely in terms of their potential energies). With this in mind then, it is perhaps better 
simply to record that both the manual docking and FlexX docking studies indicated that all 
three of the TCM compounds would be likely to form stable complexes with the aromatase 
enzyme, and that this was borne out in the experimental studies. 
 
Several recent reviews (cf. [31-32]) have attested to the benefits to be gained through the 
application of virtual screening methods in large scale data mining of natural product 
databases, with much improved levels of success seen when the phytochemical data are 
supplemented by ethnobotanical/ethnopharmacological information [33-34]. In the work 
reported here, it has been shown that the combination of a ligand-based primary in-silico 
screening followed by a protein-based secondary (in-silico) screening can provide a reliable 
means of prospecting natural product databases in the search for new leads in drug discovery. 
Given that the CHCD search database indirectly embodies ethnopharmacological information, 
the primary RF screen is both efficient in identifying suitable lead compounds, and 
sufficiently rapid that it can be used in a truly high throughput manner, permitting desktop 
processing of thousands of phytochemicals within minutes. The hits so obtained can then be 
subjected to the more stringent but more time-consuming docking studies, to identify suitable 
compounds for in-vitro testing. By such means, therefore, it will be possible more effectively 
to exploit the rich resource of plant secondary metabolites in the search for new therapeutic 
leads. 
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TABLE LEGENDS 
 
 
Table 1 
 
Phytochemicals with potential aromatase inhibitory activity: their systematic (IUPAC) names, 
botanical source(s) and Random Forest (RF) activity scores (on a scale of 0.0 – 1.0). 
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FIGURE LEGENDS 
 
 
Figure 1 
 
Chemical structures of known aromatase inhibitors: exemastane (A), aminoglutethimide (B), 
anastrozole (C) and letrosole (D). 
 
 
Figure 2 
 
Chemical structures of the potential aromatase inhibitors, liquiritigenin (A), gossypetin (B) 
and myricetin (C). 
 
 
Figure 3 
 
Molecular model of a potential complex formed between human aromatase and liquiritigenin. 
Atomic co-ordinates for the enzyme were taken from [12] and the docking of the ligand 
performed manually using Hyperchem version 7. For the protein residues, covalent geometry 
is shown using half-bond colouring, according to the colour scheme: carbon, grey; oxygen, 
red; nitrogen, blue; sulphur, yellow; and hydrogen, white. Liquiritigenin is shown in violet. 
The molecular solvent accessible surfaces are shown by means of dots, colour-coded 
according to the underlying atom type (see above). It is notable that the ligand forms no 
hydrogen bond interactions with the protein but has an L-shaped form that allows it to fit 
snugly within the available space. Selected residues within the protein active site are labelled. 
 
 
Figure 4 
 
Molecular model (derived through FlexX docking) of a potential complex formed between 
human aromatase and gossypetin. Details as for Figure 3. The dihedral angle describing the 
relative orientation of the (bicyclic) chromene and phenyl rings in the ligand is 60o. Potential 
hydrogen bonds are shown as dashed lines, and the protein residues involved are labelled. 
 
 
Figure 5 
 
Aromatase inhibitory activity of (A) liquiritigenin, (B) gossypetin, (C) myricetin and (D) 
ketaconazole (positive control), as a function of ligand concentration. Error bars show the 
standard deviations on the data (n = 4, except for ketoconazole where n = 3). Arrows indicate 
the calculated IC-50s of the inhibitors. 
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Table 1 
 
Constituent IUPAC name Botanical source(s) RF score 
Daidzein 4',7-Dihydroxyisoflavone Sophora subprostrata 0.994 
Genistein 4',5,7-Trihydroxyisoflavone Sophora subprostrata 0.990 
Galangin 3,5,7-Trihydroxyflavone Alpinia officinarum, Alpinia galanga 0.988 
Norwogonin 5,7,8-Trihydroxyflavone Scutellaria spp. 0.985 
Eriodictyol 3',4',5,7-Tetrahydroxyflavanone Many spp. 0.985 
Matairesinol 4,4'-Dihydroxy-3,3'-dimethoxylignan-9,9'-olide Arctium lappa 0.980 
Helenalin 6-Hydroxy-4-oxo-2,11(13)-pseudoguaiadien-12,8-olide Inula helenium 0.979 
Homoeryodictyol 4',5,7-Trihydroxy-3'-
methoxyflavanone Coriandrum sativum 0.975 
Liquiritigenin 4',7-Dihydroxyflavanone Dalbergia odorifera 0.973 
Demethoxycapillarisin 
5,7-Dihydroxy-2-(4-
hydroxyphenoxy)-4H-1-benzopyran-
4-one 
Artemisia capillaris 0.972 
4-Epiisoinuviscolide 4-Hydroxy-9,11(13)-guaiadien-12,8-
olide Inula helenium 0.963 
Isoliquiritigenin 2',4,4'-Trihydroxychalcone Dalbergia odorifera, Astragalus mongholicus 0.962 
Eupahakonin B 
1-Hydroxy-8-(4-hydroxy-2-
hydroxymethyl-2E-butenoyloxy)-
3,10(14),11(13)-guaiatrien-12,6-olide 
Eupatorium chinense var. 
hakonense 0.959 
Dehydrozaluzanin C 3-Oxo-4(15),10(14),11(13)-guaiatrien-12,6-olide 
Saussurea lappa (& 
Munnozia maronii) 0.958 
Hesperetin 3',5,7-Trihydroxy-4'-methoxyflavone Schizonepeta tenuifolia 0.956 
Isolicoflavonol 3,4',5,7-Tetrahydroxy-3'-prenylflavone Glycyrrhiza uralensis 0.952 
Corylinal 2-Hydroxy-5-(7-hydroxy-4-oxo-4H-1-benzopyran-3-yl)benzaldehyde Psoralea corylifolia 0.951 
2'-Hydroxygenistein 2',4',5,7-Tetrahydroxyisoflavone Lablab niger 0.941 
Licodione 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-1,3-propanedione Glycyrrhiza echinata 0.939 
Gossypetin 3,3',4',5,7,8-Hexahydroxyflavone Pyrrosia petiolosa 0.933 
Pinocembrin 5,7-Dihydroxyflavanone Glycyrrhiza spp., Alpinia katsumadai 0.930 
Scutellarein 4',5,6,7-Tetrahydroxyflavone Scutellaria spp.. 0.919 
2-Hydroxytomentosin-1,5-
epoxide 
1,5-Epoxy-2-hydroxy-4-oxo-11(13)-
xanthen-12,8-olide Xanthium strumarium 0.912 
Epiacetylaleuritolic acid 3-Acetoxy-14-taraxeren-28-oic acid Phytolacca acinosa 0.911 
2-Hydroxyalantolactone 2-Hydroxy-5,11(13)-eudesmadien-12,8-olide Inula helenium 0.910 
Apigenin 4',5,7-Trihydroxyflavone Ginkgo biloba, Pogostemon 
cablin, Coriandrum sativum 0.910 
Acacetin 5,7-Dihydroxy-4'-methoxyflavone Ginkgo biloba 0.910 
Melanoxetin 3,3',4',7,8-Pentahydroxyflavone Albizzia lebbek 0.910 
Myricetin 3,3',4',5,5',7-Hexahydroxyflavone Impatiens balsamina, Biota 
orientalis 0.905 
Melandrin 5-Hydroxy-N-(4-hydroxybenzoyl) 
anthranilic acid Melandrium firmum 0.904 
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Figure 1 
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Figure 2 
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